US FDA expands use of Novartis drug for chronic skin condition | Reuters

FDA expands Novartis remibrutinib approval for symptomatic dermographism

The FDA approved remibrutinib to treat adults with symptomatic dermographism inadequately controlled with H1 antihistamines, expanding the drug's indication beyond its initial approval.